pyrazines has been researched along with glucagon in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.38) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 11 (23.40) | 29.6817 |
| 2010's | 23 (48.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberti, KG; Catalano, C; Farrer, M; Fulcher, GR; Walker, M | 1 |
| Marco, J; Valverde, I | 1 |
| Fehlmann, M; Freychet, P; Koch, KS; Leffert, HL; Samson, M | 1 |
| Auberger, P; Le Cam, A; Samson, M | 1 |
| Cathelineau, G; Gautier, JF; Jandrain, B; Lacroix, M; Lefèbvre, PJ; Mosora, F; Pirnay, F; Scheen, AJ | 1 |
| Puhakainen, I; Yki-Järvinen, H | 1 |
| Groop, L; Härkönen, M; Melander, A; Saloranta, C; Taskinen, MR; Widen, E | 1 |
| Alberti, KG; Berrish, TS; Cooper, BG; Elliott, C; Orskov, H; Reed, JW; Walker, M | 1 |
| Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AS; Walker, M | 1 |
| Bolli, GB | 1 |
| D'Onofrio, F; Gambardella, A; Giugliano, D; Gualdiero, P; Howard, BV; Paolisso, G; Rizzo, MR; Saccomanno, F; Tagliamonte, MR | 1 |
| Marks, V; Morgan, L; Norris, F; Ranganath, L; Wright, J | 2 |
| Bjerve, KS; Grill, VE; Mostad, IL; Qvigstad, E | 1 |
| Christiansen, JS; Jørgensen, JO; Møller, N; Nielsen, S; Nørrelund, H | 1 |
| Beconi, M; Eiermann, GJ; Fisher, MH; He, H; Hickey, GJ; Kim, D; Kowalchick, JE; Leiting, B; Lyons, K; Marsilio, F; McCann, ME; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Wang, L; Weber, AE; Wu, JK; Wyvratt, MJ; Zhang, BB; Zhu, L | 1 |
| Carey, PE; Cline, GW; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Taylor, R | 1 |
| Erlich, R | 1 |
| Scheen, AJ | 1 |
| Ahrén, B | 1 |
| DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P | 1 |
| Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Svec, F | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 4 |
| Chen, B; Ernsberger, P; Escobedo, LV; Hou, D; Koletsky, MS; Koletsky, RJ; Moore, A | 1 |
| Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O | 1 |
| Elahi, D; Meneilly, GS; Stafford, S | 1 |
| Armanet, M; Burcelin, R; Cabou, C; Castel, J; Cattan, P; Drucker, DJ; Garret, C; Holst, JJ; Karaca, M; Magnan, C; Maida, A; Masseboeuf, M; Payros, G; Sulpice, T; Waget, A | 1 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Kishimoto, M; Noda, M | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
| Alba, M; Astiarraga, B; Casolaro, A; Chen, Y; Ferrannini, E; Gastaldelli, A; Holst, J; Mari, A; Muscelli, E; Seghieri, G | 1 |
| Ericsson, H; Hompesch, M; Leonsson-Zachrisson, M; Morrow, LA; Norjavaara, E; Sjöberg, F; Sjöstrand, M | 1 |
| Deacon, CF; Horowitz, M; Jones, KL; Nauck, M; Rayner, CK; Stevens, JE | 1 |
| Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W | 1 |
| Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Watanabe, K; Yamaga, M; Yokote, K | 1 |
| Gallacher, DJ; Hemmeryckx, B; Roger Lijnen, H; Rong Lu, H; Swinnen, M | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Hompesch, M; Krentz, AJ; Morrow, L; Norjavaara, E; Petersson, M | 1 |
3 review(s) available for pyrazines and glucagon
| Article | Year |
|---|---|
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
18 trial(s) available for pyrazines and glucagon
| Article | Year |
|---|---|
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glycerol; Humans; Hydrocortisone; Hydroxybutyrates; Hypolipidemic Agents; Lipolysis; Male; Middle Aged; Norepinephrine; Pyrazines | 1992 |
Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade.
Topics: Administration, Oral; Adult; Blood Glucose; C-Peptide; Calorimetry, Indirect; Carbohydrate Metabolism; Energy Metabolism; Glucagon; Glucose; Glycerol; Humans; Hypolipidemic Agents; Insulin; Lipid Metabolism; Lipolysis; Male; Oxidation-Reduction; Physical Exertion; Pyrazines | 1994 |
Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Topics: Analysis of Variance; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Lactates; Lipolysis; Liver; Male; Middle Aged; Oxygen Consumption; Pyrazines; Tritium | 1993 |
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Topics: Blood Glucose; Calorimetry; Chromatography, High Pressure Liquid; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Pyrazines; Time Factors | 1993 |
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Nitrogen; Oxygen Consumption; Pyrazines; Reference Values | 1993 |
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Topics: Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Lipid Metabolism; Male; Oxidation-Reduction; Pyrazines; Pyruvates; Radioimmunoassay; Time Factors | 1993 |
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Oxygen Consumption; Placebos; Pyrazines | 1998 |
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms | 2008 |
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Insulin; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
Topics: Adult; Azetidines; Benzamides; Body Mass Index; C-Peptide; Cross-Over Studies; Enzyme Activators; Epinephrine; Glucagon; Glucokinase; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Norepinephrine; Pyrazines; Sulfones; Young Adult | 2012 |
The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Absorption; Male; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2012 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Topics: Azetidines; Blood Glucose; Body Mass Index; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Activators; Fasting; Female; Glucagon; Glucokinase; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines | 2014 |
26 other study(ies) available for pyrazines and glucagon
| Article | Year |
|---|---|
Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects.
Topics: Administration, Oral; Arginine; Blood Glucose; Cyclohexanes; Drug Evaluation; Female; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Male; Methods; Pancreas; Pyrazines; Sulfonylurea Compounds | 1973 |
The effect of amiloride on hormonal regulation of amino acid transport in isolated and cultured adult rat hepatocytes.
Topics: Amiloride; Aminoisobutyric Acids; Animals; Biological Transport; Bucladesine; Cells, Cultured; Glucagon; Insulin; Kinetics; Liver; Male; Pyrazines; Rats | 1981 |
Insulin enhances protein phosphorylation in isolated hepatocytes by inhibiting an amiloride sensitive phosphatase.
Topics: Amiloride; Animals; Glucagon; Insulin; Liver; Male; Phosphoric Monoester Hydrolases; Phosphorylation; Proteins; Pyrazines; Rats; Rats, Inbred Strains; Stimulation, Chemical | 1982 |
Importance of catecholamines in defense against insulin hypoglycemia in humans.
Topics: Blood Glucose; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Heparin; Homeostasis; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypolipidemic Agents; Insulin; Lipolysis; Phentolamine; Propranolol; Pyrazines | 1998 |
Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.
Topics: Adult; Analysis of Variance; Area Under Curve; Case-Control Studies; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Heparin; Humans; Insulin; Models, Biological; Neurotransmitter Agents; Obesity; Peptide Fragments; Postprandial Period; Pyrazines; Triglycerides | 1999 |
The effect of circulating non-esterified fatty acids on the entero-insular axis.
Topics: Adult; Blood Glucose; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heparin; Humans; Insulin; Intestines; Islets of Langerhans; Obesity; Peptide Fragments; Protein Precursors; Pyrazines | 1999 |
Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Proteins; Energy Intake; Exercise; Fasting; Fatty Acids; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Proinsulin; Pyrazines | 2003 |
Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting.
Topics: Adult; Amino Acids; Blood Flow Velocity; Blood Glucose; Calorimetry, Indirect; Fasting; Fatty Acids, Nonesterified; Forearm; Glucagon; Glucose Clamp Technique; Glycerol; Human Growth Hormone; Humans; Insulin; Insulin Resistance; Lactic Acid; Lipolysis; Male; Microdialysis; Plethysmography; Pyrazines; Somatostatin | 2004 |
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Binding Sites; Biochemistry; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Precursors; Pyrazines; Rats; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2005 |
Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
Topics: Adult; Blood Glucose; C-Peptide; Fatty Acids, Nonesterified; Female; Food; Glucagon; Glucose; Glycerol; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Oxidation-Reduction; Placebos; Pyrazines; Triglycerides | 2005 |
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines | 2005 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2009 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
A diabetes drug, sitagliptin, also has a potential to prevent diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Topics: Adult; Animals; Blood Glucose; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Vagus Nerve | 2011 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Topics: Animals; C-Peptide; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Treatment Outcome; Triazoles; Umbilical Cord | 2014 |
Sitagliptin improves postprandial hyperglycemia by inhibiting glucagon secretion in Werner syndrome with diabetes.
Topics: Diabetes Mellitus; Female; Glucagon; Humans; Hyperglycemia; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Werner Syndrome | 2013 |
Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Heart; Heart Function Tests; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardium; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |